Standard BioTools Inc [LAB] stock is trading at $2.59, up 0.39%. An important factor to consider is whether the stock is rising or falling in short-term value. The LAB shares have gain 2.37% over the last week, with a monthly amount glided 1.17%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Standard BioTools Inc [NASDAQ: LAB] stock has seen the most recent analyst activity on April 16, 2024, when TD Cowen initiated its Buy rating and assigned the stock a price target of $3.50. Previously, Jefferies started tracking the stock with Buy rating on April 04, 2024, and set its price target to $3.25. On July 12, 2023, KeyBanc Capital Markets initiated with a Overweight rating and assigned a price target of $4 on the stock.
Standard BioTools Inc [LAB] stock has fluctuated between $1.57 and $3.16 over the past year. Currently, Wall Street analysts expect the stock to reach $3.25 within the next 12 months. Standard BioTools Inc [NASDAQ: LAB] shares were valued at $2.59 at the most recent close of the market. An investor can expect a potential return of 25.48% based on the average LAB price forecast.
Analyzing the LAB fundamentals
Standard BioTools Inc [NASDAQ:LAB] reported sales of 126.76M for the trailing twelve months, which represents a growth of 81.30%. Gross Profit Margin for this corporation currently stands at 0.49% with Operating Profit Margin at -0.73%, Pretax Profit Margin comes in at -0.71%, and Net Profit Margin reading is -0.71%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.73 and Total Capital is -0.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.53 points at the first support level, and at 2.47 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.65, and for the 2nd resistance point, it is at 2.72.
Ratios To Look Out For
For context, Standard BioTools Inc’s Current Ratio is 4.50. On the other hand, the Quick Ratio is 4.17, and the Cash Ratio is 2.36. Considering the valuation of this stock, the price to sales ratio is 7.83, the price to book ratio is 1.71.
Transactions by insiders
Recent insider trading involved Casdin Partners Master Fund, L, Director, that happened on May 22 ’24 when 0.15 million shares were purchased. Director, Casdin Partners Master Fund, L completed a deal on May 21 ’24 to buy 0.35 million shares. Meanwhile, Director Casdin Partners Master Fund, L bought 100000.0 shares on May 20 ’24.
